mTelehealth Announces Positive Outcomes of Remote Patient Monitoring in Feasibility Study With Leading U.S. Medical Institution

Results demonstrate mTelehealth’s Remote Patient Monitoring interventions for Cardiovascular Disease survivors were highly effective and yielded positive health outcomes

Delray Beach, FL, July 28, 2020 — mTelehealth, LLC, a premier provider of Remote Patient Monitoring solutions, today announced positive results from a telehealth feasibility study it conducted with City of Hope National Medical Center, the Beckman Research Institute of City of Hope, and other leading U.S. medical institutions, demonstrating the benefits of mTelehealth’s Remote Patient Monitoring (RPM) Telehealth Kit for Cardiovascular Disease (CVD) patients.

The study, “Feasibility and Acceptability of Using a Telehealth Platform to Monitor Cardiovascular Risk Factors in Hematopoietic Cell Transplantation Survivors at Risk for Cardiovascular Disease,” confirmed that mTelehealth’s RPM Telehealth Kit is a feasible and highly acceptable platform to monitor modifiable risk factors in Hematopoietic Cell Transplantation survivors at risk for CVD.

Study participants received mTelehealth’s RPM Telehealth Kit, which includes Bluetooth-enabled devices such as a blood pressure monitor, weight scale, and pulse oximeter, and a 4G-enabled Gateway that allows data transfer from the devices to the cloud-based mTelehealth Patient Portal.

Preliminary study findings concluded that mTelehealth’s RPM Telehealth Kit facilitated the development of CVD interventions in large groups of survivors at a fraction of the cost and resources necessary to deliver preventive and long-term survivorship care. The study showed high levels of patient compliance and involvement, better blood pressure control, and improved health-seeking behaviors. Additionally, more than 85%
of participants agreed that the study allowed them to be more active in managing their health and kept them motivated.

“The results of this study, conducted with some of the finest healthcare institutions in the world and offered to high-risk patients, confirm the fundamental value proposition of Remote Patient Monitoring for Cardiovascular Disease patients,” stated Marc Poulshock, President and CEO of mTelehealth. “The COVID-19 global pandemic, which is causing a shortage of hospital capacity and straining healthcare workers, underscores the critical need to empower patients and medical professionals to use telehealth, telemedicine, and RPM to manage and improve care without stepping foot in a hospital or doctor’s office.”

“Our partnership with mTelehealth was critical to the success of this project, and has set the stage for paradigm-changing research in the near future,” stated Saro Armenian, D.O., Department of Population Sciences, City of Hope. “During these unprecedented times, it is imperative that we continue to explore new approaches to quality healthcare delivery for our most vulnerable and at- risk patients.”

The study was conducted with Children’s Hospital Los Angeles, City of Hope National Medical Center, Perelman School of Medicine at the University of Pennsylvania, Seattle Children’s Hospital, and the Beckman Research Institute of City of Hope. mTelehealth’s RPM telehealth solution is eligible for CMS reimbursement under Current Procedure Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes including 99091, 99446, 99447, 99448, 99449, 99451, 99452, 99453, 99454, 99457, 99458, G2012, G2010, G0513, and G0514.

About mTelehealth
mTelehealth, LLC, founded in 2010 and based in Delray Beach, FL, is a premier provider of Remote Patient Monitoring (RPM), Telemedicine, Chronic Care Management (CCM), Virtual Exam, Video Visit, and related Telehealth solutions. Our Remote Health Monitoring System, Powered by aTouchAway™, provides a complete solution to remotely collect, store, and report timely and accurate health information anywhere. We connect patients with their families and care providers through our easy-to-use, affordable, remote health monitoring kit. For more information, visit our website:, Facebook, LinkedIn, and Twitter.

Marc Poulshock